View : 24 Download: 3

Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

Title
Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
Authors
Lee, Ju YupKim, NayoungPark, Kyung SikKim, Hyun JinPark, Seon MeeBaik, Gwang HoShim, Ki-NamOh, Jung HwanChoi, Suck CheiKim, Sung EunKim, Won HeePark, Seon-YoungKim, Gwang HaLee, Bong EunJo, YunjuHong, Su Jin
Ewha Authors
심기남
SCOPUS Author ID
심기남scopus
Issue Date
2016
Journal Title
BMC GASTROENTEROLOGY
ISSN
1471-230XJCR Link
Citation
vol. 16
Keywords
Helicobacter pyloriEradicationAmoxicillinTetracyclineBismuthQuadruple
Publisher
BIOMED CENTRAL LTD
Indexed
SCIE; SCOPUS WOS scopus
Abstract
Background: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy. Methods: In total, 390 H. pylori-infected subjects participated in the randomized clinical trial: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day). C-13-urea breath test, rapid urease testing, or histology was performed to check for eradication. Results: Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 % and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040). Conclusions: Ten-day sequential therapy appears to be more effective despite frequent adverse events. However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %. Additional trials are needed to identify a more satisfactory first-line eradication therapy.
DOI
10.1186/s12876-016-0490-8
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
Comparison of sequential therapy and amoxicillin tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori.pdf(552.36 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE